New Century Financial Group LLC Has $337,000 Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

New Century Financial Group LLC cut its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.0% during the 4th quarter, HoldingsChannel reports. The fund owned 827 shares of the pharmaceutical company’s stock after selling 62 shares during the quarter. New Century Financial Group LLC’s holdings in Vertex Pharmaceuticals were worth $337,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of VRTX. Public Sector Pension Investment Board raised its holdings in Vertex Pharmaceuticals by 72.9% in the 2nd quarter. Public Sector Pension Investment Board now owns 9,844 shares of the pharmaceutical company’s stock valued at $4,614,000 after acquiring an additional 4,151 shares in the last quarter. Insigneo Advisory Services LLC raised its stake in Vertex Pharmaceuticals by 107.1% in the second quarter. Insigneo Advisory Services LLC now owns 1,249 shares of the pharmaceutical company’s stock valued at $596,000 after purchasing an additional 646 shares in the last quarter. Deerfield Management Company L.P. Series C bought a new stake in Vertex Pharmaceuticals during the second quarter worth about $598,000. Daymark Wealth Partners LLC grew its stake in Vertex Pharmaceuticals by 38.9% during the second quarter. Daymark Wealth Partners LLC now owns 782 shares of the pharmaceutical company’s stock worth $367,000 after buying an additional 219 shares in the last quarter. Finally, MBB Public Markets I LLC raised its position in shares of Vertex Pharmaceuticals by 2,398.5% in the 2nd quarter. MBB Public Markets I LLC now owns 18,114 shares of the pharmaceutical company’s stock valued at $8,490,000 after buying an additional 17,389 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on VRTX. Oppenheimer cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Monday, January 13th. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Friday, December 20th. Canaccord Genuity Group lifted their target price on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a research report on Wednesday, November 6th. Finally, HC Wainwright dropped their target price on shares of Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating for the company in a report on Friday, December 20th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $494.84.

Vertex Pharmaceuticals Trading Down 0.0 %

Shares of VRTX opened at $439.62 on Friday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The firm’s fifty day simple moving average is $435.88 and its two-hundred day simple moving average is $464.95. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. During the same quarter in the prior year, the company earned $3.67 EPS. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.